3/5
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
3/3
02:33 am
mdgl
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success [Yahoo! Finance]
2/25
09:40 am
mdgl
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra's Near US$1 Billion Debut Year [Yahoo! Finance]
Low
Report
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra's Near US$1 Billion Debut Year [Yahoo! Finance]
2/25
04:15 am
mdgl
Madrigal: The Easiest Money May Have Been Made [Seeking Alpha]
Low
Report
Madrigal: The Easiest Money May Have Been Made [Seeking Alpha]
2/24
08:00 am
mdgl
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
2/24
06:47 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
2/20
08:03 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target lowered by analysts at Bank of America Corporation from $570.00 to $529.00. They now have a "neutral" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target lowered by analysts at Bank of America Corporation from $570.00 to $529.00. They now have a "neutral" rating on the stock.
2/19
07:05 pm
mdgl
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... [Yahoo! Finance]
2/19
12:45 pm
mdgl
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/19
10:39 am
mdgl
Madrigal Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Madrigal Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/19
07:00 am
mdgl
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Medium
Report
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
2/17
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2/17
08:22 am
mdgl
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday [Seeking Alpha]
Medium
Report
Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday [Seeking Alpha]
2/15
10:29 am
mdgl
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Medium
Report
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/11
06:49 am
mdgl
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Low
Report
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
2/11
06:31 am
mdgl
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Low
Report
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
2/11
06:25 am
mdgl
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Low
Report
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
2/11
05:00 am
mdgl
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
Low
Report
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
2/5
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2/2
08:05 am
mdgl
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Low
Report
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
1/29
07:41 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
06:00 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/22
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
1/21
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
1/20
09:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $527.00 to $745.00. They now have a "market outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $527.00 to $745.00. They now have a "market outperform" rating on the stock.